Auscan Resources (OTC:AHELF) Stock, Quote.Headers.trade-ideas

Auscan Resources Inc is a Canada-based company. Its principal activity was the acquisition, exploration, and development of helium property interests in North America. Currently, the company does not have any mineral property interests and is looking for a new business opportunity.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABEO

ADAP

ADTR

ADXS

AETUF

AGHI

ALKS

AMGDF

ARGGY

ASMB

ASNA

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATRA

AVRI

AXAS

BCEFF

BCEL

BDIC

BEWFF

BGFV

BIEI

BJCHY

BJRI

BKRIF

BKUT

BLIN

BMYMP

BNDSF

BNDSY

BNIKF

BOTH

BRSWQ

CAIXY

CARB

CBGPY

CBIS

CDEV

CEIX

CESDF

CGLDF

CHKDG

CINR

CLUB

CLVS

CMSQY

CNKEF

COIHF

CORV

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTRA

CUAEF

Changyou Limited American Depositary Share

CYOU

CYTX

DBLVF

DCTH

DKGH

DLTH

DMIFF

DNJR

DPDW

DPGYF

DVAX

ETRN

EVAHF

EXPR

FCUUF

FELP

FNJN

FOMX

FPLSF

FRAC

FURGF

FVANF

GARB

GNFT

GPOR

GTHR

Stocks That Managed to Breach 52-Week Lows Friday

Auscan Resources Inc

<p>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares are trading higher Monday after the company <a href="https://www.benzinga.com/pressreleases/25/01/g42942645/salarius-pharmaceuticals-and-decoy-therapeutics-announce-definitive-merger-agreement">announced a merger agreement</a> with Decoy Therapeutics, a privately held biopharmaceutical company. </p>
<p><strong>What To Know:</strong> Under the agreement, Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals to form a new entity called Decoy Therapeutics. Following the merger and a shareholder vote to convert preferred shares into common stock, Decoy investors are expected to hold approximately 86% of the combined company, with Salarius shareholders retaining about 14%.</p>
<p>Decoy's platform centers on developing peptide conjugate therapeutics aimed at treating respiratory viruses and cancer. The combined company plans to fast-track clinical development by leveraging Decoy's innovative pipeline and approximately $7 million in non-dilutive funding from sources like the Bill &amp; Melinda Gates Foundation and other partners.</p>
<p>Additionally, Salarius' cancer drug candidates, including SP-3164 and seclidemstat, will be integrated into the development plans, with ongoing support for a Phase 1/2 clinical trial for seclidemstat at MD Anderson Cancer Center.</p>
<p>The merger is expected to enable progress in several areas over the next 12 months. Decoy plans to file an Investigational New Drug application with the FDA for its lead pan-coronavirus antiviral and advance programs targeting flu, COVID-19 and gastrointestinal cancers. Salarius also expects updates from its MD Anderson clinical trial involving patients with myelodysplastic syndrome and chronic myelomonocytic leukemia.</p>
<p><strong>SLRX Price Action:</strong> Salarius shares were up 155.3% at $4.02 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13132002/Screenshot-2025-01-13-at-13.18.46-1024x535.png" alt="" class="wp-image-731076" style="width:497px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13132002/Screenshot-2025-01-13-at-13.18.46-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13132002/Screenshot-2025-01-13-at-13.18.46-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13132002/Screenshot-2025-01-13-at-13.18.46-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13132002/Screenshot-2025-01-13-at-13.18.46.png 1514w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/entertainment/25/01/42956034/netflix-stock-has-long-term-runway-for-dominance-in-streaming-analyst-highlights-4-key-catalysts">Netflix Stock Has &#8216;Long Term Runway For Dominance In Streaming&#8217;: Analyst Highlights 4 Key Catalysts</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


SLRX

Salarius Pharmaceuticals Shares Are Skyrocketing Today: What's Going On?

Biotech

ARAY

Accuray Incorporated  Announced the Company's Radixact Sync System And Cyberknife S7 System Have Been Approved By The Chinese National Medical Products Administration

<p><a href="https://www.wsj.com/business/hospitality/hanging-out-at-starbucks-you-now-need-to-order-something-e9ab07bf" title="https://www.wsj.com/business/hospitality/hanging-out-at-starbucks-you-now-need-to-order-something-e9ab07bf">https://www.wsj.com/business/hospitality/hanging-out-at-starbucks-you-now-need-to-order-something-e9ab07bf</a></p>


SBUX

Starbucks to Roll Out New Code of Conduct, Require Cafe Users to Be Paying Customers

<p>In the last three months, 12 analysts have published ratings on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $215.67, along with a high estimate of $298.00 and a low estimate of $167.00. A decline of 0.95% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798453_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Texas Instruments. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$208.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$190.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$167.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Texas Instruments. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Texas Instruments's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Texas Instruments's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Texas Instruments analyst ratings.</strong></a></p>
<h2>All You Need to Know About Texas Instruments</h2>
<p>Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.</p>
<h3>Unraveling the Financial Story of Texas Instruments</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Texas Instruments's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-8.41%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Texas Instruments's net margin excels beyond industry benchmarks, reaching <strong>32.64%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Texas Instruments's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.86%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Texas Instruments's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.85%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.84</strong>, Texas Instruments faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Texas Instruments Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

<p>In the last three months, 15 analysts have published ratings on Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $55.13, a high estimate of $75.00, and a low estimate of $33.00. Observing a 38.76% increase, the current average has risen from the previous average price target of $39.73. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798445_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Doximity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Doximity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Doximity compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Doximity's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Doximity's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOCS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Doximity analyst ratings.</strong></a></p>
<h2>Discovering Doximity: A Closer Look</h2>
<p>Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.</p>
<h3>Doximity's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Doximity's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>20.44%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>32.27%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.71%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.03%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Doximity's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DOCS

Demystifying Doximity: Insights From 15 Analyst Reviews

<p>In the preceding three months, 7 analysts have released ratings for Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.14, a high estimate of $25.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.44%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798438_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Chemours by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Chemours. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Chemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Chemours's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Chemours analyst ratings.</strong></a></p>
<h2>Delving into Chemours's Background</h2>
<p>The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.</p>
<h3>Breaking Down Chemours's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Chemours displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.94%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Chemours's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1.8%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Chemours's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.91%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Chemours's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-0.37%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Chemours's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>6.53</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Chemours Through 7 Analysts

<p>Ratings for Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Lazard, presenting an average target of $59.2, a high estimate of $65.00, and a low estimate of $52.00. This current average is unchanged from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798430_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Lazard among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$57.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$59.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lazard. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lazard compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Lazard's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Lazard's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LAZ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lazard analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lazard</h2>
<p>Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.</p>
<h3>Unraveling the Financial Story of Lazard</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Lazard's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>49.05%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Lazard's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>13.3%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lazard's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>19.46%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lazard's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.25%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Lazard's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.8</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Lazard Through The Eyes Of 5 Analysts

<p>Financial giants have made a conspicuous bearish move on Eos Energy Enterprises. Our analysis of options history for Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $157,500, and 6 were calls, valued at $306,487.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $1.0 and $7.5 for Eos Energy Enterprises, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Eos Energy Enterprises stands at 14349.0, with a total volume reaching 5,643.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eos Energy Enterprises, situated within the strike price corridor from $1.0 to $7.5, throughout the last 30 days.</p>
<h3>Eos Energy Enterprises Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798429_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EOSE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.25</td>
<td>$2.16</td>
<td>$2.25</td>
<td>$5.00</td>
<td>$112.5K</td>
<td>125</td>
<td>500</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.9</td>
<td>$2.97</td>
<td>$3.75</td>
<td>$1.00</td>
<td>$88.5K</td>
<td>15.2K</td>
<td>255</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$1.00</td>
<td>$55.5K</td>
<td>15.2K</td>
<td>411</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.53</td>
<td>$0.49</td>
<td>$0.54</td>
<td>$7.50</td>
<td>$53.4K</td>
<td>10.9K</td>
<td>2.1K</td>
</tr>
<tr>
<td>EOSE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.37</td>
<td>$0.94</td>
<td>$2.25</td>
<td>$5.00</td>
<td>$45.0K</td>
<td>125</td>
<td>700</td>
</tr>
</tbody>
</table>
</p>
<h3>About Eos Energy Enterprises</h3>
<p>Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial &amp; industrial (C&amp;I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.</p>
<p>In light of the recent options history for Eos Energy Enterprises, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Eos Energy Enterprises's Current Market Status</h3>
<ul>
<li>With a volume of 6,884,820, the price of EOSE is down -3.83% at $4.77. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 49 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eos Energy Enterprises options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

EOSE

This Is What Whales Are Betting On Eos Energy Enterprises

<p>Financial giants have made a conspicuous bearish move on KLA. Our analysis of options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 28% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $395,190, and 8 were calls, valued at $1,431,673.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $600.0 to $710.0 for KLA over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for KLA options trades today is 170.5 with a total volume of 1,180.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for KLA's big money trades within a strike price range of $600.0 to $710.0 over the last 30 days.</p>
<h3>KLA Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798424_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$91.6</td>
<td>$87.9</td>
<td>$89.1</td>
<td>$600.00</td>
<td>$267.3K</td>
<td align="right">107</td>
<td align="right">191</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$87.8</td>
<td>$86.9</td>
<td>$87.8</td>
<td>$600.00</td>
<td>$263.4K</td>
<td align="right">107</td>
<td align="right">151</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$89.3</td>
<td>$82.4</td>
<td>$85.9</td>
<td>$600.00</td>
<td>$257.7K</td>
<td align="right">107</td>
<td align="right">90</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$87.3</td>
<td>$84.8</td>
<td>$87.3</td>
<td>$600.00</td>
<td>$253.1K</td>
<td align="right">107</td>
<td align="right">60</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$80.0</td>
<td>$73.4</td>
<td>$76.6</td>
<td>$600.00</td>
<td>$229.8K</td>
<td align="right">107</td>
<td align="right">30</td>
</tr>
</tbody>
</table>
</p>
<h3>About KLA</h3>
<p>KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.</p>
<p>Having examined the options trading patterns of KLA, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of KLA</h3>
<ul>
<li>With a volume of 591,675, the price of KLAC is down -1.22% at $674.71. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 17 days.</li>
</ul>
<h3>What Analysts Are Saying About KLA</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $777.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on KLA, which currently sits at a price target of $795.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on KLA with a target price of $759. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest KLA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


KLAC

Smart Money Is Betting Big In KLAC Options

<p>Analysts' ratings for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $766.5, a high estimate of $850.00, and a low estimate of $703.00. Experiencing a 5.17% decline, the current average is now lower than the previous average price target of $808.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798421_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive KLA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$795.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Toshiya Hari</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$759.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$800.00</td>
<td>$870.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$703.00</td>
<td>$746.00</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$725.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$750.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Edward Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$850.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Sidney Ho</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$750.00</td>
<td>$890.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to KLA. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KLA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of KLA's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of KLA's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KLAC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on KLA analyst ratings.</strong></a></p>
<h2>About KLA</h2>
<p>KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.</p>
<h3>Understanding the Numbers: KLA's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> KLA's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>18.55%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> KLA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>33.29%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>27.3%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> KLA's ROA excels beyond industry benchmarks, reaching <strong>6.08%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.92</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 8 Analysts Discuss KLA Stock

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>First Solar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FSLR, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 27 uncommon options trades for First Solar.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 44%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $318,015, and 21 are calls, for a total amount of $1,445,637.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $95.0 to $260.0 for First Solar over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for First Solar's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across First Solar's significant trades, within a strike price range of $95.0 to $260.0, over the past month.</p>
<h3>First Solar Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798418_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$107.0</td>
<td>$104.45</td>
<td>$105.11</td>
<td>$95.00</td>
<td>$273.8K</td>
<td>48</td>
<td align="right">28</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.26</td>
<td>$1.95</td>
<td>$1.95</td>
<td>$250.00</td>
<td>$165.5K</td>
<td>4.7K</td>
<td align="right">857</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$67.85</td>
<td>$65.9</td>
<td>$66.76</td>
<td>$160.00</td>
<td>$133.5K</td>
<td>14</td>
<td align="right">30</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.9</td>
<td>$10.8</td>
<td>$10.89</td>
<td>$230.00</td>
<td>$115.5K</td>
<td>223</td>
<td align="right">167</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$79.6</td>
<td>$79.05</td>
<td>$79.6</td>
<td>$260.00</td>
<td>$79.6K</td>
<td>549</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About First Solar</h3>
<p>First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.</p>
<p>Following our analysis of the options activities associated with First Solar, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of First Solar</h3>
<ul>
<li>Trading volume stands at 971,243, with FSLR's price down by -2.97%, positioned at $183.62.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>Professional Analyst Ratings for First Solar</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $241.33333333333334.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on First Solar, which currently sits at a price target of $248.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on First Solar, which currently sits at a price target of $267.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for First Solar, targeting a price of $209. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for First Solar with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


FSLR

Decoding First Solar's Options Activity: What's the Big Picture?

<p>In the latest quarter, 5 analysts provided ratings for Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $45.6, a high estimate of $47.00, and a low estimate of $44.00. This current average has increased by 0.88% from the previous average price target of $45.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798413_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Vontier by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Robert Jamieson</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vontier. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vontier compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Vontier's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Vontier's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VNT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vontier analyst ratings.</strong></a></p>
<h2>Delving into Vontier's Background</h2>
<p>Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2023.</p>
<h3>Vontier: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Vontier faced challenges, resulting in a decline of approximately <strong>-2.01%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Vontier's net margin excels beyond industry benchmarks, reaching <strong>12.24%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Vontier's ROE excels beyond industry benchmarks, reaching <strong>8.95%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vontier's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.15%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Vontier's debt-to-equity ratio surpasses industry norms, standing at <strong>2.18</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Vontier Stands With Analysts

<p>Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) has outperformed the market over the past 10 years by 4.94% on an annualized basis producing an average annual return of 16.08%. Currently, Raymond James Finl has a market capitalization of $31.53 billion. </p>
<p><strong>Buying $1000 In RJF:</strong> If an investor had bought $1000 of RJF stock 10 years ago, it would be worth <strong>$4,440.23</strong> today based on a price of $154.52 for RJF at the time of writing.</p>
<h3>Raymond James Finl's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736798408_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

<p>Shares of<strong> Intra-Cellular Therapies Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) are trading higher Monday after <strong>Johnson &amp; Johnson</strong> agreed to <a href="https://www.benzinga.com/pressreleases/25/01/g42940221/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-i">acquire the company</a>.</p>
<p><strong>What To Know: </strong>Johnson &amp; Johnson on Monday entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion. </p>
<p>The acquisition is expected to strengthen Johnson &amp; Johnson&#8217;s presence in neuroscience, and includes Intra-Cellular Therapies&#8217; CAPLYTA (lumateperone), a once-daily oral treatment approved by the FDA for schizophrenia and depressive episodes linked to bipolar I and II disorder.</p>
<p>Johnson &amp; Johnson also gains a pipeline, including ITI-1284, which is being tested for generalized anxiety disorder and Alzheimer's-related psychosis and agitation.</p>
<p>In December 2024, Intra-Cellular Therapies submitted a supplemental new drug application for CAPLYTA as an adjunctive treatment for major depressive disorder. If approved, the drug could become a key player in treating common depressive disorders, potentially generating over $5 billion in annual sales.</p>
<p>The transaction is expected to close later this year, pending regulatory and shareholder approvals. Once completed, Intra-Cellular Therapies&#8217; stock will be delisted from the Nasdaq. Johnson &amp; Johnson plans to fund the acquisition with cash on hand and debt. Johnson &amp; Johnson is also expected to provide commentary on any potential impact to adjusted earnings when it reports financial results on Jan. 22. </p>
<p><strong>ITCI Price Action:</strong> Intro-Cellular shares were up 34.2% at $127.27 at the time of writing Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1024x523.png" alt="" class="wp-image-731191" style="width:493px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1536x784.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08.png 1546w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns">ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns</a></strong></li>
</ul>
<p><em>Photo by solarseven on Shutterstock</em>.</p>


ITCI

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?

<p><strong>Broadcom Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is currently navigating a <a href="https://www.benzinga.com/quote/AVGO/news">moderately bullish trend</a> while grappling with slight selling pressure.</p>
<h1 class="wp-block-heading"><strong>Broadcom Stock: Mixed Technical Signals</strong></h1>
<p><figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13134115/Screenshot-2025-01-14-at-12.10.59-AM.png" alt="" class="wp-image-731109" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13134115/Screenshot-2025-01-14-at-12.10.59-AM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13134115/Screenshot-2025-01-14-at-12.10.59-AM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure></p>
<p><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011425&amp;t=be2bearmibe3na1"><em>Chart created using Benzinga Pro</em></a></p>
<p>Broadcom stock price sits at $226.01, revealing a complex picture when juxtaposed with technical indicators. Its eight-day and 20-day simple moving averages (SMA) at $230.13 and $229.71 respectively, flash bearish signals.</p>
<p>However, the broader outlook offers bullish sentiment, as Broadcom stock remains above the 50-day SMA of $194.52 and the 200-day SMA of $164 — indicators pointing toward a continued uptrend.</p>
<p>Further supporting optimism, Broadcom stock's Moving Average Convergence Divergence (MACD) indicator stands at a bullish 10.33, while the Relative Strength Index (RSI) hovers at a stable 56.26, suggesting neither overbought nor oversold conditions.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum">Nvidia, Broadcom, Marvell Positioned For Growth As AI Demand Drives Semiconductor Momentum</a></strong></p>
<h1 class="wp-block-heading"><strong>$3 Billion Senior Notes Issued For Strategic Flexibility</strong></h1>
<p>In a significant move to bolster its financial position, Broadcom <a href="https://investors.broadcom.com/node/62851/html">issued</a> $3 billion in senior notes through underwriters led by Wells Fargo and Citigroup. The issuance is split into three tranches:</p>
<ul>
<li>$1.1 billion in 4.800% notes due 2028, </li>
<li>$800 million in 5.050% notes due 2030, and </li>
<li>$1.1 billion in 5.200% notes due 2032. </li>
</ul>
<p>The unsecured notes will rank equally with Broadcom's other debts and are earmarked for general corporate purposes, including debt repayment.</p>
<p>Despite a current debt-to-equity ratio of 1.02, Broadcom&#8217;s strategic use of capital underscores its confidence in sustaining market leadership, particularly amid AI-driven growth opportunities.</p>
<h1 class="wp-block-heading"><strong>AI Revenue, Long-Term Growth Prospects</strong></h1>
<p>Broadcom's recent fiscal performance underscores its resilience, with AI-related revenue driving better-than-expected fourth-quarter results. The company anticipates $14.6 billion in revenue and an EBITDA margin of approximately 66% for the upcoming quarter, cementing its position alongside <strong>NVIDIA Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the AI infrastructure race.</p>
<p>As market dynamics shift and Broadcom fortifies its financial strategy, investors are eyeing the long-term value the semiconductor giant continues to offer amid evolving technological landscapes.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/42896233/japanese-chipmaker-rapidus-sets-sights-on-broadcom-to-emulate-taiwan-semiconductors-market-dominance">Japanese Chipmaker Rapidus Sets Sight on Broadcom to Emulate Taiwan Semiconductor&#8217;s Market Dominance</a></strong></li>
</ul>
<p><em>Photo: Rokas Tenys via Shutterstock</em></p>


Long Ideas

Bonds

Technicals

Tech

AVGO

NVDA

Broadcom's $3 Billion Bet: Balancing Market Signals, AI-Driven Growth

<p>-Reuters, citing conference presentation</p>


Health Care

GILD

Gilead Exec Says Co Expects To Do "Something Like A Cymabay Acquisition Every Couple Of Years

<p>A <strong>United Airlines Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) analyst says the company could mirror recent earnings strength and guidance that <strong>Delta Air Lines</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) had when the company reports fourth-quarter financial results <a href="https://www.benzinga.com/earnings">on Jan. 21.</a></p>
<p><strong>The United Airlines Analyst</strong>: Bank of America analyst<strong> Andrew Didora</strong> reiterated a Buy rating on United Airlines and raised the price target from $100 to $120.</p>
<p><strong>The Analyst Takeaways</strong>: United Airlines could be the biggest winner from a strong outlook<a href="https://www.benzinga.com/25/01/42912208/delta-stock-jumps-after-record-q4-earnings-and-strong-2025-outlook"> shared by Delta, </a>Didora said in a new investor note.</p>
<p>"We expect UAL to report strong 4Q24 results and guide 1Q25 ahead of consensus when the company reports earnings on 1/21," Didora said.</p>
<p>The analyst raised fourth quarter, first quarter and full year 2025 earnings per share estimates ahead of the earnings report.</p>
<p>"The airline is the biggest beneficiary of the strong premium, corporate, and transatlantic growth mentioned in DAL's earnings report last week."</p>
<p>Didora said United's premium product offering and coastal hubs that see strong corporate share should see the airline company reporting results in line with Delta or better.</p>
<p>"The magnitude of DAL's +7-9% 1Q25 revenue guide was a positive surprise to us, and this outlook was well ahead of our prior/Visible Alpha consensus 1Q25 revenue growth forecast of +6.0% for UAL."</p>
<p>The analyst estimates UAL could see 7.5% year-over-year growth in the first quarter based on Delta's report.</p>
<p>"We are modeling consistent unit revenue growth throughout 2025 of around 3% for total revenue growth of +7.6%."</p>
<p>The analyst said the new forecast should allow United to see both higher earnings and free cash flow, allowing the company to complete its buyback and see "further de-leveraging."</p>
<p><strong>UAL Price Action</strong>: United Airlines stock is down 3.32% to $103.52 at publication Monday versus a 52-week trading range of $37.02 to $110.92. United Airlines stock is up 164% over the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/travel/24/12/42450095/us-airlines-set-to-fly-high-in-2025-analyst-says-perfect-storm-of-tailwinds-will-propel-industry-gains">US Airlines Set To Fly High In 2025, Analyst Says: &#8216;Perfect Storm Of Tailwinds&#8217; Will Propel Industry Gains</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Price Target

Previews

Reiteration

Travel

United Airlines Earnings Preview: Could Airline Impress Investors After Delta's Strong Guidance?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Riot Platforms</strong>.</p>
<p>Looking at options history for Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) we detected 21 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 42% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $96,145 and 18, calls, for a total amount of $1,300,893.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $8.0 and $20.0 for Riot Platforms, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Riot Platforms options trades today is 19933.44 with a total volume of 90,039.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Riot Platforms's big money trades within a strike price range of $8.0 to $20.0 over the last 30 days.</p>
<h3>Riot Platforms 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736797543_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.43</td>
<td>$1.44</td>
<td>$14.00</td>
<td>$247.1K</td>
<td>32.9K</td>
<td>43.7K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.37</td>
<td>$1.37</td>
<td>$14.00</td>
<td>$201.2K</td>
<td>32.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.42</td>
<td>$1.37</td>
<td>$1.42</td>
<td>$14.00</td>
<td>$142.1K</td>
<td>32.9K</td>
<td>3.1K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$17.00</td>
<td>$133.6K</td>
<td>6.5K</td>
<td>494</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$12.00</td>
<td>$80.7K</td>
<td>7.2K</td>
<td>884</td>
</tr>
</tbody>
</table>
</p>
<h3>About Riot Platforms</h3>
<p>Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.</p>
<p>Having examined the options trading patterns of Riot Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Riot Platforms Standing Right Now?</h3>
<ul>
<li>With a trading volume of 16,240,684, the price of RIOT is down by -5.5%, reaching $11.34.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Riot Platforms</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $23.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $23. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Riot Platforms, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RIOT

Riot Platforms's Options Frenzy: What You Need to Know

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Amgen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for <strong>Amgen</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 27% bullish and 63%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $306,375, and 10, calls, for a total amount of $382,064.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $220.0 to $300.0 for Amgen during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1857.57 with a total volume of 1,376.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $220.0 to $300.0 over the last 30 days.</p>
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736797538_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$14.25</td>
<td>$14.2</td>
<td>$14.25</td>
<td>$260.00</td>
<td>$306.3K</td>
<td align="right">231</td>
<td align="right">109</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$46.0</td>
<td>$44.15</td>
<td>$46.0</td>
<td>$220.00</td>
<td>$73.6K</td>
<td align="right">239</td>
<td align="right">9</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$14.7</td>
<td>$14.35</td>
<td>$14.7</td>
<td>$290.00</td>
<td>$63.2K</td>
<td align="right">60</td>
<td align="right">43</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.3</td>
<td>$3.15</td>
<td>$3.3</td>
<td>$300.00</td>
<td>$40.9K</td>
<td align="right">493</td>
<td align="right">129</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.25</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$290.00</td>
<td>$35.4K</td>
<td align="right">158</td>
<td align="right">94</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<p>Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 1,552,050, the price of AMGN is down by -0.1%, reaching $261.96.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $296.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Amgen, targeting a price of $280.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Amgen with a target price of $298.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $310. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


AMGN

Unpacking the Latest Options Trading Trends in Amgen

<p>Financial giants have made a conspicuous bearish move on Qualcomm. Our analysis of options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) revealed 31 unusual trades.</p>
<p>Delving into the details, we found 29% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $951,965, and 17 were calls, valued at $1,247,474.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $105.0 to $170.0 for Qualcomm during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Qualcomm's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Qualcomm's whale trades within a strike price range from $105.0 to $170.0 in the last 30 days. </p>
<h3>Qualcomm Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736797533_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.7</td>
<td>$140.00</td>
<td>$295.6K</td>
<td>1.8K</td>
<td align="right">384</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.7</td>
<td>$3.55</td>
<td>$3.65</td>
<td>$105.00</td>
<td>$164.2K</td>
<td>2.8K</td>
<td align="right">472</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.3</td>
<td>$27.2</td>
<td>$27.2</td>
<td>$150.00</td>
<td>$147.0K</td>
<td>1.4K</td>
<td align="right">130</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$32.95</td>
<td>$31.8</td>
<td>$31.8</td>
<td>$135.00</td>
<td>$146.2K</td>
<td>33</td>
<td align="right">0</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$38.85</td>
<td>$38.6</td>
<td>$38.6</td>
<td>$130.00</td>
<td>$131.2K</td>
<td>677</td>
<td align="right">62</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<p>After a thorough review of the options trading surrounding Qualcomm, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Qualcomm</h3>
<ul>
<li>Trading volume stands at 2,864,603, with QCOM's price down by -0.13%, positioned at $156.78.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 16 days.</li>
</ul>
<h3>Professional Analyst Ratings for Qualcomm</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $215.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Qualcomm with a target price of $215. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Qualcomm, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


QCOM

Behind the Scenes of Qualcomm's Latest Options Trends

Auscan Resources

American Helium

Comments

Auscan Resources

Auscan Resources (AHELF) Forecast

Auscan Resources (OTC:AHELF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga